AN2 Therapeutics director granted 20,400 stock options

AN2 Therapeutics, Inc. director Melvin K. Spigelman reported receiving a grant of stock options covering 20,400 shares of the company’s stock.

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. director Melvin K. Spigelman reported receiving a grant of stock options covering 20,400 shares of the company’s stock. The award was recorded as an acquisition of derivative securities held directly by him. According to the filing, these option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date.

Insider Trade Summary

Grant/Award: 20,400 shares

Grant/Award 1 txn

Insider Spigelman Melvin K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 contracts (Direct)

Footnotes (1)

1. F1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report in this Form 4?

The Form 4 reports that director Melvin K. Spigelman received a grant of stock options for 20,400 shares of AN2 Therapeutics common stock. This is reported as an acquisition of derivative securities held directly by the reporting person.

How many stock options did Melvin K. Spigelman receive from AN2 Therapeutics (ANTX)?

Melvin K. Spigelman was granted stock options covering 20,400 shares of AN2 Therapeutics common stock. The filing shows his total derivative holdings as 20,400 option shares following the transaction, all reported as directly owned by him.

When do the AN2 Therapeutics (ANTX) option shares granted to Melvin K. Spigelman vest?

The option shares are scheduled to vest on February 20, 2027. Vesting is conditioned on Melvin K. Spigelman continuing to provide service to AN2 Therapeutics through that date, according to the footnote included in the filing.

Was there any sale of AN2 Therapeutics (ANTX) shares reported in this Form 4?

No sales were reported in this Form 4. The transaction summary shows one acquisition transaction and zero sales or dispositions, reflecting only the grant of 20,400 stock options to director Melvin K. Spigelman.

How is Melvin K. Spigelman’s ownership of the AN2 Therapeutics (ANTX) options classified?

The filing classifies Melvin K. Spigelman’s ownership of the 20,400 stock option shares as direct. The ownership code is listed as “D,” and no indirect ownership entity or special beneficial ownership disclaimer is indicated in the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spigelman Melvin K

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		(1)	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Melvin K. Spigelman	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.